NewsBenzingaMorgan Stanley belässt Mirum Pharmaceuticals auf „Overweight“ und erhöht das Kursziel auf 152 US-Dollar Morgan Stanley belässt Mirum Pharmaceuticals auf „Overweight“ und erhöht das Kursziel auf 152 US-Dollar Benzinga 2026.10.13 10:04 (GMT+0) Open on Benzinga Other news Stocks Supported by a Rebound in Chipmakers and AI-Infrastructure Companies Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know. Rocket Lab's Biggest Technological Advantage Is Fast Becoming Its Biggest Problem Why Is IREN Stock Surging Monday? Venture Global Stock Just Secured a Data Center Win. How to Play It Here. PrimeXBT Launches 14-Day VIP Welcome Offer, Cutting Trading Costs for All New Users
Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know.
